439192
Last Update Posted: 2007-08-08
Recruiting has ended
All Genders accepted | 18 Years + |
275 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.
Eligibility
Relevant conditions:
Overactive Bladder
Urinary Incontinence
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov